300683.SHE Wuhan Hiteck Biological Pharma Co Ltd
- Market cap
- CNY 2.81B
- P/E
- -
- P/B
- 1.40x
- ROE
- -7.8%
- Dividend yield
- 0.64%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300683.SHE undervalued?
Graham numberThe Graham number of Wuhan Hiteck Biological Pharma Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Wuhan Hiteck Biological Pharma Co Ltd fundamental analysis
No fundamental analysis for Wuhan Hiteck Biological Pharma Co Ltd yet.
Wuhan Hiteck Biological Pharma Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Wuhan Hiteck Biological Pharma Co Ltd
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the production and sales of bioengineering products and lyophilized powder injections in China and internationally. The company operates through Biopharmaceutical Division; Pharmaceutical Technology Services Division; In Vitro Diagnostic Reagents Division; Production and Sales Division of Active Pharmaceutical Ingredients and Pharmaceutical Intermediates; and Other Divisions segments. Its product…
Full company profileWuhan Hiteck Biological Pharma Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Wuhan Hiteck Biological Pharma Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 771M | 750M | 591M | 620M | 524M | 615M | 689M | 602M | 649M | 541M | 418M |
| Gross Profit | 735M | 715M | 546M | 500M | 309M | 350M | 330M | 233M | 268M | 231M | 128M |
| Operating Income | 182M | 156M | 105M | 75.1M | -35.1M | 21.3M | -6.82M | -143M | -75.7M | -122M | -164M |
| EBITDA | 199M | 183M | 119M | 95.8M | -7.91M | 56.6M | 44.5M | -80.9M | 9.74M | -140M | -179M |
| Net Income | 157M | 142M | 94.1M | 63.0M | -25.0M | 27.7M | -14.0M | -121M | -69.3M | -231M | -159M |
| EPS | 2.03 | 1.65 | 0.91 | 0.61 | -0.24 | 0.26 | -0.11 | -0.93 | -0.53 | -1.77 | -1.21 |
| Balance Sheet | |||||||||||
| Total Assets | 1.04B | 1.91B | 2.16B | 2.17B | 2.19B | 2.70B | 2.71B | 2.97B | 2.94B | 2.58B | 2.41B |
| Total Liabilities | 336M | 266M | 446M | 409M | 462M | 354M | 371M | 476M | 525M | 407M | 366M |
| Shareholders' Equity | 697M | 1.64B | 1.70B | 1.75B | 1.71B | 2.32B | 2.31B | 2.48B | 2.39B | 2.16B | 2.04B |
| Cash & Short-term Investments | 608M | 698M | 307M | 1.18B | 711M | 698M | 893M | 1.09B | 869M | 648M | 138M |
| Total Debt | 2.45M | 2.45M | 2.45M | 2.45M | 6.49M | 111M | 103M | 44.0M | 24.1M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 144M | 83.1M | 73.4M | 63.0M | -19.7M | 12.1M | 53.0M | 5.31M | 22.7M | -76.5M | - |
| Capital Expenditure | 22.1M | 22.3M | 38.7M | 116M | 114M | 247M | 174M | 167M | 43.1M | 50.5M | 31.9M |
| Free Cash Flow | 122M | 60.8M | 34.8M | -53.1M | -133M | -235M | -121M | -162M | -20.4M | -127M | -40.1M |
| Ratios | |||||||||||
| ROE | 22.5% | 8.7% | 5.5% | 3.6% | -1.5% | 1.2% | -0.6% | -4.9% | -2.9% | -10.7% | -7.8% |
| ROA | 15.1% | 7.5% | 4.4% | 2.9% | -1.1% | 1.0% | -0.5% | -4.1% | -2.4% | -9.0% | -6.6% |
| Net Profit Margin | 20.4% | 19.0% | 15.9% | 10.2% | -4.8% | 4.5% | -2.0% | -20.1% | -10.7% | -42.7% | -38.0% |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.05x | 0.04x | 0.02x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Wuhan Hiteck Biological Pharma Co Ltd dividends
- Dividend yield
- 0.64%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jan 9, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 17.9M | 0.14 | - |
| 2024 | CNY 1.76M | 0.01 | - |
| 2023 | CNY 2.20M | 0.02 | - |
| 2022 | CNY 1.34M | 0.01 | - |
| 2021 | CNY 62.0K | 0.00 | 0.2% |
| 2020 | CNY 16.5M | 0.16 | - |
| 2019 | CNY 20.7M | 0.20 | 32.8% |
| 2018 | CNY 31.2M | 0.30 | 33.1% |
| 2017 | CNY 31.0M | 0.36 | 21.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Wuhan Hiteck Biological Pharma Co Ltd
- Insiders 45.53%
- Institutions 1.96%
- Public & others 52.51%
- Shares outstanding 131M
- Free float 73.3M
Wuhan Hiteck Biological Pharma Co Ltd company profile
- Company name
- Wuhan Hiteck Biological Pharma Co Ltd
- Ticker
- 300683.SHE
- ISIN
- CNE1000034C5
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 958
- Fiscal year end
- December
- Address
- Haite Science and Technology Park, Wuhan, China, 430056
- Phone
- 86 27 8489 1666
- Website
- hiteck.com.cn
About Wuhan Hiteck Biological Pharma Co Ltd
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the production and sales of bioengineering products and lyophilized powder injections in China and internationally. The company operates through Biopharmaceutical Division; Pharmaceutical Technology Services Division; In Vitro Diagnostic Reagents Division; Production and Sales Division of Active Pharmaceutical Ingredients and Pharmaceutical Intermediates; and Other Divisions segments. Its products include Epramine for injection; mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis; tinidazole suppository, acyclovir dispersible tablets, nimodipine extended-release tablets, trimetazidine hydrochloride tablets, azithromycin granules, esomeprazole sodium for injection, and cyclic adenosine monophosphate for injection; Pentoxone theobromine injection; Roxatidine Acetate Hydrochloride for Injection; and Terizazole phosphate for injection. The company also provides measles and rubella virus nucleic acid detection kits; isolation and identification tubes and kits for mycoplasma; and bacterial vaginosis (BV) rapid test kits, as well as diagnostic kits for novel coronavirus N-Protein, as well as raw materials and intermediates. In addition, it offers diagnostic kits for IgG antibody to measles virus, hydatid, toxoplasma, rubella virus, cytomegalo virus, and herpes simplex virus I/II; diagnostic kits for IgM antibody to measles virus, herpes simplex virus I/II, cytomegalo virus, rubella virus, and toxoplasma; and diagnostic kits for a "Thalassemia. Further, the company provides Lopinavir and Ritonavir APIs, and intermediates. It offers its products in the field of nervous system and oncology. Wuhan Hiteck Biological Pharma Co.,Ltd was founded in 1992 and is based in Wuhan, China.
Wuhan Hiteck Biological Pharma Co Ltd management
3- Ms. Wen XianFinancial Director, Accounting Supervisor & Non-Independent Director · born 1975
- Mr. Huang ChenDeputy GM & Director · born 1975
- Mr. Kun YangSecretary of Board of Directors · born 1987